Testing a new combination treatment for advanced liver cancer after initial therapy fails

Plain-English translation of NCT07219459 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether visugromab, combined with two other medications ( and ), can help people with advanced liver cancer whose initial treatment stopped working. About half of participants will receive the three-medication combination, while the other half will receive just plus placebo injections. The goal is to see if this new combination helps people live longer and keeps their cancer under control.

Many people with advanced liver cancer don't respond well enough to their first treatment, and their cancer continues to grow. This trial is exploring whether adding this medication to existing treatments can give patients a better chance of controlling their cancer when their initial therapy has failed.

Do you qualify?

You likely qualify if…

you have been diagnosed with unresectable or metastatic hepatocellular carcinoma (advanced liver cancer that cannot be surgically removed)
you have tried one line of prior treatment that included an approved immunotherapy drug and were treated with it for at least 12 weeks
you have measurable disease visible on imaging scans
you are at least 18 years old
you have a life expectancy of at least 3 months as assessed by your doctor
you have a Child-Pugh score of A6 or better, meaning your liver is functioning reasonably well despite the cancer

You likely don't qualify if…

you have received more than one line of prior systemic chemotherapy or immunotherapy for your advanced liver cancer
you have an active autoimmune disease requiring treatment in the past 3 months
you have had a recent heart attack, heart inflammation, or stroke within the past 3 months
you have active inflammatory bowel disease or other serious gastrointestinal conditions
you have had a prior liver transplant or other organ transplant

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new three-medication combination given as injections and an oral pill, or oral plus placebo injections. You will visit the clinic regularly for treatment, blood tests, and imaging scans to monitor how you're responding. The trial has a safety run-in phase first, followed by the main treatment phase where 40 people in each treatment group will be studied.

AI-generated summary from trial data · Aug 12, 2026 · Not medical advice

Testing a new combination treatment for advanced liver cancer after initial therapy fails

What is this trial?

Do you qualify?

What participation looks like

Trial locations